Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleDetermination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat
dc.contributor.authorYang, X.
dc.contributor.authorHu, Z.
dc.contributor.authorSui, Y.C.
dc.contributor.authorHo, P.C.
dc.contributor.authorChan, E.
dc.contributor.authorZhou, S.
dc.contributor.authorDuan, W.
dc.contributor.authorBoon, C.G.
dc.identifier.citationYang, X., Hu, Z., Sui, Y.C., Ho, P.C., Chan, E., Zhou, S., Duan, W., Boon, C.G. (2005). Determination of thalidomide by high performance liquid chromatography: Plasma pharmacokinetic studies in the rat. Journal of Pharmaceutical and Biomedical Analysis 39 (1-2) : 299-304. ScholarBank@NUS Repository.
dc.description.abstractA sensitive and simple high performance liquid chromatography (HPLC) method was developed and validated for the determination of thalidomide in rat plasma. Chromatography was accomplished with a reversed-phase Hypersil C18 column. Mobile phase consisted of acetonitrile-10 mM ammonium acetate buffer (pH 5.50) (28:72, v/v), at a flow rate of 0.8 ml/min. Thalidomide was monitored by ultraviolet detector at 220 nm and it gave a linear response as a function of concentration over 0.02-50 μM. The limit of quantitation in rat plasma was 0.50 ng (0.02 μM plasma concentration) with an aliquot of 20 μl. Results from a 3-day validation study indicated that this method allows for simple and rapid quantitation of thalidomide with excellent accuracy and reliability. Using this validated assay, the effect of coadministered irinotecan (CPT-11) on the plasma pharmacokinetics of thalidomide in rats was determined. Coadministration of CPT-11 (intravenously, 60 mg/kg) increased the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC 0-10 h) of thalidomide by 32.29 and 11.66%, respectively, as compared to the control, but none of the effect of CPT-11 was of statistical significance (P > 0.05). Concomitant CPT-11 also caused a 10.04% decrease in plasma clearance (CL) and 14.51% decrease in volume of distribution (V d) (P > 0.05). These results suggest that coadministered CPT-11 did not significantly alter the plasma pharmacokinetics of thalidomide in rats. Further studies are warranted to explore the pharmacokinetic and pharmacodynamic interactions between CPT-11 and thalidomide. © 2005 Elsevier B.V. All rights reserved.
dc.description.sourcetitleJournal of Pharmaceutical and Biomedical Analysis
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.